Novel targets for therapeutic intervention in inflammatory bowel disease. What is the best way to assess the safety profile of a drug?

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The emergence of biologic therapies has revolutionized the management of inflammatory bowel disease (IBD) by halting disease progression, increasing remission rates and improving long-term clinical outcomes. Despite these well-described benefits, many patients are reluctant to commence therapy due to drug safety concerns. Adverse events can be detected at each stage of drug development and during the post-marketing period. In this article, we review how to best assess the safety parameters of new IBD medications, from the earliest stage of development to population-based registries, with a focus on the special populations often excluded from the evaluation process.

Original languageEnglish
Pages (from-to)57-63
Number of pages7
JournalCurrent Pharmaceutical Design
Volume25
Issue number1
DOIs
StatePublished - 2019

Keywords

  • Adverse effect
  • Biologics
  • Clinical trials
  • Drug development
  • Inflammatory bowel disease
  • Safety
  • Side effect

Fingerprint

Dive into the research topics of 'Novel targets for therapeutic intervention in inflammatory bowel disease. What is the best way to assess the safety profile of a drug?'. Together they form a unique fingerprint.

Cite this